Iconocast Logo

Welcome To Iconocast

How to add a URL link from your web site to the Iconocast web sites

Virtual tour of Southern California

 

Recent News and Articles on the Keywords: 2006 + pst + web  Related to the article below (Last Update: 8/4/2008)

citizen journalism,
CNET News, CA - Jul 10, 2008
By Josh Lowensohn ? February 14, 2008 4:45 PM PST 2 comments As we wrote on Monday, CNN's citizen journalism pet project iReport was due to get a site of ...

paidContent
Interview: Andrew Paulson, CEO, Sup: Russia?s Web Revolution ...
paidContent, UK - Jul 23, 2008
By Robert Andrews - Wed 23 Jul 2008 04:00 AM PST The first most people heard of Sup was when the upstart Moscow internet investment vehicle bought ...
MOT?RHEAD: Audio Samples Of Entire 'Mot?rizer' Album Available ...
Blabbermouth.net, NY - Aug 1, 2008
COM Monday nights between 7 and 9 pm PST (and again on Sunday mornings between 7 and 9 am). Lemmy was interviewed on July 3, 2008 in Berlin, Germany about ...
Even As Local Online Ad Spend Surges, Newspapers Can?t Win
paidContent.org, CA - Jul 30, 2008
By David Kaplan - Wed 30 Jul 2008 09:16 PM PST In the daily drumbeat of bad news for newspapers, the growth of online advertising would seem to offer some ...LOCM
Males, war and PTSD
Mountain Xpress, NC - Jul 29, 2008
Call (888) 777-4443 (9 am to 9 pm PST, seven days a week); http://www.nvf.org. The state?s close ties to the military reflect a pattern seen throughout the ...
PEER 1 Servers Face Downtime
Web Host Industry Review - Jul 16, 2008
According to several reports, an explosion caused by a circuit failure just before 9:00 am PST knocked out an entire BC hydro substation, cutting power to ...PINK:PNWKF

paidContent.org
Interview: Perkins Miller, SVP-Digital Media, NBC Sports ...
paidContent.org, CA -
By Staci D. Kramer - Mon 04 Aug 2008 10:45 AM PST The Beijing Games begin in four days?and with them, the most complicated, intensive digital media Olympics ...
Firefox claims download success
Australia.TO, Australia - Jul 20, 2008
The attempt to set the download record was scheduled to begin at 1300 PST (2000 GMT) on 17 June. However, the record attempt was almost wrecked from the ...
STEVEN ADLER Makes Bail, Is Released From Police Custody - July 18 ...
Blabbermouth.net, NY - Jul 18, 2008
According to the web site of The Los Angeles County Sheriff's Department, former GUNS N' ROSES drummer Steven Adler was released from police custody at 5:28 ...

Bay Area Indymedia
Free Gaza Radio Show w' Wallach, Wang, Epstein, Berlin, Hughes ...
Bay Area Indymedia, CA - Jul 18, 2008
In 2006 he volunteered with Palestine Medical Relief Society for one month in the North West Bank and in Gaza. His photo-journals from both trip are posted ...
Source: Google News

[PDF] Model Transformations for Integrating and Validating Web Application Models
A Knapp, G Zhang - Proc. of Modellierung, 2006 - pst.ifi.lmu.de
... Ludwig-Maximilians-Universitat Munchen {knapp, zhangg}@pst.ifi.lmu.de Abstract:
While most current Web Engineering methodologies model the separate aspects ...

Model transformations from requirements to web system design
N Koch, G Zhang, MJ Escalona - Proceedings of the 6th international conference on Web …, 2006 - portal.acm.org
... 67 80538 M?nchen, Germany zhangg@pst.ifi.lmu.de ... Web Engineering is a concrete domain
where MDD may be helpful [11 ... owner(s). ICWE'06, July 11-14, 2006, Palo Alto ...

[BOOK] Web engineering -
N Koch, P Fraternali, M Wirsing - 2004 - wwwcs.uni-paderborn.de
... 1 Web Engineering Winter Term 2006/07 Prof. ... http://www.pst.informatik.uni-muenchen.
de/kochn/index.html ? W. Schwinger, N. Koch: Modeling Web Applications. ...

Events -
PST Access - The Journal of Thoracic and Cardiovascular Surgery, 2004 - AATS/WTSA
... Office/ATCSA Secretar- iat, 2F, Philippine Heart Centre, East Ave, Quezon City 1100,
Philippines (Web site: www.atcsa.org; E-mail: infoAatcsa.org). June 2006 ...

The Journal of Thoracic and Cardiovascular Surgery
PST Access - The Journal of Thoracic and Cardiovascular Surgery, 2001 - AATS/WTSA
... http://jtcs.ctsnetjournals.org/cgi/content/full/122/1/3 the World Wide Web at: The
online version ... on December 2, 2006 jtcs.ctsnetjournals.org Downloaded from ...

Editorial Board: 2002-2003
PST Access - The Journal of Thoracic and Cardiovascular Surgery, 2002 - AATS/WTSA
... http://jtcs.ctsnetjournals.org/cgi/content/full/124/1/8 located on the World Wide
Web at: The ... on October 17, 2006 jtcs.ctsnetjournals.org Downloaded from ...

Giant benign localized fibrous tumor of the pleura Ruffini et al. Eur J Cardiothorac Surg. 1998; 14: …
S In, PST Access, S Up - European Journal of Cardio-thoracic Surgery - EACTS
... This information is current as of October 26, 2006 http://ejcts.ctsnetjournals.org/
cgi/content/full/14/3/340 located on the World Wide Web at: The online ...

The Annals of Thoracic Surgery
PST Access - The Annals of Thoracic Surgery, 2002 - Soc Thorac Surgeons
... ats.ctsnetjournals.org/cgi/content/full/73/1/1 on the World Wide Web at: The ... at Google
Indexer on December 13, 2006 ats.ctsnetjournals.org Downloaded from ...

Retrograde perfusion of oxygenated blood during off pump revascularization to avoid... Bedi and …
S In, PST Access, S Up - European Journal of Cardio-thoracic Surgery - EACTS
... This information is current as of November 29, 2006 http://ejcts.ctsnetjournals.
org/cgi/content/full/17/2/193 located on the World Wide Web at: The online ...
-

Re: In vivo model for reversal of pulmonary blood flow in canines. Rao Eur J Cardiothorac Surg. 2000 …
S In, PST Access, S Up - European Journal of Cardio-thoracic Surgery - EACTS
... This information is current as of October 9, 2006 http://ejcts.ctsnetjournals.org/
cgi/content/full/18/1/124 located on the World Wide Web at: The online ...
-

Source: Google Scholar
 
 

New Options To Treat Chronic Myeloid Leukemia, Overcome Imatinib Resistance

Article Date: 11 Dec 2006 - 0:00am (PST)
The development of the targeted anticancer medicine imatinib has been a landmark event in the treatment of patients with chronic myeloid leukemia (CML), a cancer of the bone marrow. However, over time, the cancer can become resistant to this treatment, usually because of mutations in the protein that imatinib targets. Two studies being presented today at the 48th Annual Meeting of the American Society of Hematology (ASH(TM)) highlight new compounds in development that can effectively treat CML when imatinib is no longer effective.

"This is important progress for patients who relapse on imatinib therapy," said Charles A. Linker, MD, University of California, San Francisco. "Not only does this research show the efficacy of new treatments for imatinib- resistant disease, it also demonstrates the value of looking at each patient's mutation pattern to determine an individual course of therapy."

Hematologic and Cytogenetic Response Dynamics to Nilotinib (AMN 107) Depend on the Type of BCR-ABL Mutations in Patients with Chronic Myelogenous Leukemia (CML) after Imatinib Failure [Abstract #749]

Article continues below and (thank you)
 
Treatment with imatinib has allowed patients with chronic myelogenous leukemia (CML) to experience a nearly 90 percent five-year survival rate, as the drug blocks the tyrosine kinase BCR-ABL, an abnormal protein driving the overproduction of abnormal white blood cells characteristic of leukemia. However, many patients have eventually developed resistance to this treatment because their cancer cells are able to mutate and adapt, causing their disease to relapse.

Researchers studied nilotinib, a novel treatment that blocks the BCR-ABL protein, to determine its effectiveness among patients for whom imatinib has stopped working. In vitro work showed effectiveness even in patients developing BCR-ABL mutations associated with resistance to imatinib. Investigators looked at blood samples from 101 CML patients, 64 of whom were in the early or chronic phase, 22 in the later or accelerated phase, and 15 in the final or blast crisis phase of the disease, and screened for the BCR-ABL gene mutation that signals CML.

Prior to treatment with nilotinib, researchers found 28 different BCR-ABL mutations in 61 patients. Of this group, nine showed two mutations, three showed three mutations, and one patient showed four mutations. When treated with nilotinib twice a day (400 mg), 70 percent of patients with mutations experienced a hematologic response, with the highest rate of response seen in patients in the chronic phase (78 percent), followed by accelerated phase (75 percent) and blast crisis (25 percent). Patients without mutations responded even better to the therapy, as 88 percent experienced a hematologic response rate.

Chronic phase patients whose genetic mutations had shown sensitivity to nilotinib in the lab achieved a complete cytogenetic response within three to six months. Two patients with the BCR-ABL mutation T315I -- a mutation highly resistant to both imatinib and nilotinib in the lab -- showed no signs of relapse of disease after one month and 11 months of treatment with nilotinib, respectively.

"This preliminary data suggests that nilotinib may help patients for whom imatinib has stopped working by overcoming the gene mutations that cause imatinib resistance," said Andreas Hochhaus, MD, of the Medical Faculty Mannheim of the University of Heidelberg, Germany. "It also shows the importance of determining each patient's specific gene mutation, to apply individualized dosage of nilotinib according to the mutation pattern."

Response to Dasatinib after Imatinib Failure According to Type of Preexisting BCR-ABL Mutations [Abstract #748]

Dasatinib blocks the production of BCR-ABL and it has been shown to treat CML and ALL that have become resistant to the standard therapy of imatinib.

This study looked at the type of gene mutations that are more responsive to treatment with dasatinib to confirm the best targets for future therapy. Blood samples from 394 patients being treated with dasatinib (198 chronic phase, 78 accelerated phase, 53 myeloid blast crisis, and 65 lymphoid blast crisis/ALL) were monitored in three month intervals to determine how the preexisting genetic mutations responded to the therapy and if new mutations emerged. Prior to treatment, 46 different BCR-ABL mutations were detected in 202 patients -- 162 patients showed one, 33 patients showed two, six patients showed three, and one patient showed four mutations.

Patients with mutations responded well to therapy, as complete hematologic response was achieved in 91 percent of chronic phase patients, 62 percent of accelerated phase patients, 41 percent of myeloid blast crisis patients, and 34 percent of lymphoid blast crisis/ALL patients. Complete cytogenetic responses were similar and occurred in 37 percent of chronic phase patients, 27 percent of accelerated phase patients, 28 percent of myeloid blast crisis patients, and 51 percent of lymphoid blast crisis patients.

Researchers observed two response patterns in studying treatment with dasatinib: some patients experienced a decrease in the BCR-ABL expression and the proportion of the mutated clone simultaneously, while others experienced a decrease in BCR-ABL followed by a decrease of the mutated clone after a delay of four to six months. Five patients developed new mutations associated with resistance to dasatinib, including T315I. The T315I mutation is highly resistant to both imatinib and dasatinib.

"Dasatinib is an excellent treatment option for patients who have become resistant to imatinib," said lead researcher, Martin C. Muller, MD, Medical Faculty Mannheim of the University of Heidelberg, Germany. "However, we noted that response depended heavily on the type of genetic mutation, which may signal a method for individualizing each patient's dose."

The American Society of Hematology (http://www.hematology.org) is the world's largest professional society concerned with the causes and treatment of blood disorders. Its mission is to further the understanding, diagnosis, treatment, and prevention of disorders affecting blood, bone marrow, and the immunologic, hemostatic, and vascular systems, by promoting research, clinical care, education, training, and advocacy in hematology.

American Society of Hematology
http://www.hematology.org
 
 
 
Google
Web www.iconocast.com
 
 
 

 

Continue News With: News9A ;